comparemela.com

Latest Breaking News On - Nurexone biologic inc - Page 12 : comparemela.com

United States Patent Office Allows Patent to Exosome

The patent covers Nurexone’s ExoPTEN drug compositions and treatment methods for Central Nervous System disease.

United statesLior shaltielInbar paz benayounHead of communicationsCompany or nurexoneTrademark officeNurexone biologic incIsrael institute of technologyVenture exchangeTel aviv universityRegulation services providerExone biologicUnited states patentTechnion israel instituteSpecial shareholderIsrael institute

NurExone Biologic Inc : United States Patent Office Allows Patent to Exosome Biomedical Company NurExone

The patent covers NurExone's ExoPTEN drug compositions and treatment methods for Central Nervous System disease Haifa, Israel and Calgary, Alberta (Newsfile Corp. - January 12, 2023) - NurExone Biologic

United statesNurexone exoLior shaltielCompany or nurexoneTrademark officeNurexone biologic incIsrael institute of technologyAlberta newsfile corpVenture exchangeTel aviv universityRegulation services providerCentral nervous systemExone biologicUnited states patentTechnion israel instituteSpecial shareholder

2023-01-12 | TSXV:NRX | Press Release | NurExone Biologic Inc

(2023-01-12 | TSXV:NRX) United States Patent Office Allows Patent to Exosome Biomedical Company NurExone

United statesNurexone exoLior shaltielCompany or nurexoneTrademark officeNurexone biologic incIsrael institute of technologyAlberta newsfile corpVenture exchangeTel aviv universityRegulation services providerCentral nervous systemExone biologicUnited states patentTechnion israel instituteSpecial shareholder

NurExone Biologic Inc : NurExone Issues Annual Shareholder Letter

Calgary, Alberta (Newsfile Corp. - December 15, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) ("we", "our", the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided

Israel generalUnited statesUnited kingdomLior shaltielLyora aharonovShulamit levenbergCompany or nurexoneDean of the biomedical engineering departmentNurexone biologic incAlberta newsfile corpVenture exchangeRegulation services providerDrug administrationYissum research development companyNanometrix ltdIsrael institute of technology

2022-12-15 | TSXV:NRX | Press Release | NurExone Biologic Inc

(2022-12-15 | TSXV:NRX) NurExone Issues Annual Shareholder Letter

Israel generalUnited statesUnited kingdomLior shaltielLyora aharonovShulamit levenbergCompany or nurexoneDean of the biomedical engineering departmentNurexone biologic incAlberta newsfile corpVenture exchangeRegulation services providerDrug administrationYissum research development companyNanometrix ltdIsrael institute of technology

vimarsana © 2020. All Rights Reserved.